Related Experiment Video
Updated: Jun 6, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Bendamustine: new perspective for an old drug in lymphoproliferative disorders
Marco Montillo1, Francesca Ricci, Alessandra Tedeschi
1Department of Oncology/Haematology, Division of Haematology, Niguarda Ca'Granda Hospital, Piazza Ospedale Maggiore 3, Milan, Italy. marco.montillo@ospedaleniguarda.it
Abstract:
Bendamustine is an old bifunctional alkylating agent that also has potential antimetabolite properties, and only partial cross-resistance with other alkylators. Although it was synthesized in 1963 only few validated study results exist from this early period. More recently, its peculiar mechanism of action has reawakened interest in this drug that has been extensively studied in indolent non-Hodgkin lymphoma (NHL) and in chronic lymphocytic leukemia (CLL). Experience has also been reported in high-grade NHL and Hodgkin disease. Based on its unique structure, various strategies can be used for mechanism-based combination chemotherapeutic regimens with bendamustine. Moreover, data indicates that bendamustine when combined with rituximab is a valid therapeutic choice for patients with CLL or low-grade NHL demonstrating refractoriness to standard chemotherapy regimens. Furthermore, its documented favorable toxicity profile makes it a particularly useful treatment option for elderly patients.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Abnormal Proliferation
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...